Baricitinib Provides Significant Hair Regrowth in Adolescents with Severe Alopecia Areata: 52-Week Efficacy and Safety Results from a Phase 3 Randomized, Controlled Trial

A Phase 3 randomized, controlled trial with 257 adolescents aged 12 to <18 years with severe alopecia areata (AA) found that baricitinib, especially at a 4-mg dose, significantly promotes hair regrowth over 52 weeks. More than 50% of participants on the 4-mg dose achieved significant scalp hair regrowth, with a 71% response rate among those with a baseline SALT score of 50-94. The 2-mg dose also showed positive results. The safety profile was consistent with previous data, with no new safety concerns and no serious adverse events reported. Common adverse events included acne and upper respiratory infections.